Literature DB >> 21323397

Pain freedom at 2 hours in migraine after telcagepant 300 mg.

Peer Tfelt-Hansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21323397     DOI： 10.2165/11587770-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  10 in total

1.  Guidelines for controlled trials of drugs in migraine: second edition.

Authors:  P Tfelt-Hansen; G Block; C Dahlöf; H C Diener; M D Ferrari; P J Goadsby; V Guidetti; B Jones; R B Lipton; H Massiou; C Meinert; G Sandrini; T Steiner; P B Winter
Journal:  Cephalalgia       Date:  2000-11       Impact factor: 6.292

Review 2.  Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.

Authors:  Peer Tfelt-Hansen
Journal:  Headache       Date:  2010-11-10       Impact factor: 5.887

3.  Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.

Authors:  Paul L Durham; Carrie V Vause
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 4.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

5.  Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.

Authors:  M D Ferrari; P J Goadsby; K I Roon; R B Lipton
Journal:  Cephalalgia       Date:  2002-10       Impact factor: 6.292

6.  What do patients with migraine want from acute migraine treatment?

Authors:  Richard B Lipton; Sandra W Hamelsky; Jeffrey M Dayno
Journal:  Headache       Date:  2002-01       Impact factor: 5.887

7.  Randomized, controlled trial of telcagepant for the acute treatment of migraine.

Authors:  K M Connor; R E Shapiro; H-C Diener; S Lucas; J Kost; X Fan; K Fei; C Assaid; C Lines; Tony W Ho
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

8.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

10.  Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database.

Authors:  Hans Christoph-Diener; Michel Ferrari; Hank Mansbach
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.